March 29, 2011 11:08 ET

Prescription Pharmaceutical Sales Will Shrink by $108 Billion Due to the Patent Cliff

ROCKVILLE, MD--(Marketwire - March 29, 2011) - has announced the addition of Datamonitor's new report "Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview" to their collection of Pharma market reports. For more information, visit

Prescription pharmaceutical sales in the world's major markets (US, France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China and India) totaled $555bn in 2009, having grown by 6.3% during 2008-09, and at a compound annual growth rate (CAGR) of 5.6% between 2005 and 2009.

  • Examines the prescription pharmaceutical sales growth trends across the various different therapy areas
  • Assesses the leading prescription pharmaceutical brands across each of the 12 major pharma markets
  • Profiles the leading multinational and domestic pharma companies operating in each of the 12 major pharma markets
  • Analyzes the forecast sales according to lifecycle stage of drug, molecule type, source of drug, geographical market, therapy area and formulation

The US prescription pharmaceutical market generated half (50.3%) of the sales of the 12 markets analyzed, with $279bn in 2009, with sales having grown by 5.0% (CAGR, 2005-09) and 5.5% (2008-09). However, future sales growth will be shaped by three key events: the US economic downturn, healthcare reform and the patent cliff.

Pharma is set to lose approximately $108bn in sales due to the patent cliff during 2010-15, while the industry is also feeling the effect of the recent global economic downturn. However, Pharma is implementing a number of strategies to drive sales and profitability going forward: product innovation, diversification and cost-containment.

Growth in the emerging markets is driven by their rapidly growing economies and populations; expansion of healthcare systems and health insurance policies, increasing access to drugs; and the emergence of middle classes with disposable incomes, who are more likely to spend money on branded generics and branded pharmaceuticals.

For more information, visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact